Enter assignee name

Trademarks = 2

Forward Citations = 5

Loading Chart...

6 inventors (with patents filed for the assignee):

Jason Allan Wiles (7 out of 80 patents)

Mark George Saulnier (7 out of 40 patents)

Kevin Tyler Sprott (7 out of 7 patents)

4. Srinivasa Karra (7 out of 7 patents)

5. Jesse Jingyang Chen (7 out of 7 patents)

6. Soumya Ray (7 out of 7 patents)

7 patents: Sort by Forward Citations

1. 12312340 - Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins (2025-05-27),

2. 12290568 - ASGPR-binding compounds for the degradation of extracellular proteins (2025-05-06),

3. 12280116 - ASGPR-binding compounds for the degradation of extracellular proteins (2025-04-21),

4. 12128106 - ASGPR-binding compounds for the degradation of extracellular proteins (2024-10-29),

5. 12091402 - Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins (2024-09-17),

6. 12076408 - ASGPR-binding compounds for the degradation of extracellular proteins (2024-09-03),

7. 11819551 - ASGPR-binding compounds for the degradation of extracellular proteins (2023-11-21),

Avilar Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for the treatment of serious diseases. With a mission to advance patient care, Avilar leverages its proprietary platform to identify and optimize biologic therapies. The company's approach emphasizes precision medicine and aims to address unmet medical needs across various therapeutic areas, including oncology and autoimmune disorders. By harnessing cutting-edge science and technology, Avilar is committed to transforming potential discoveries into effective treatments that enhance the quality of life for patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

7 Patents

#140 in Waltham, MA

#2,243 in Massachusetts

#38,834 in US

Waltham, MA, United States of America

Avilar Therapeutics, Inc.